MGRX Company Profile and Key Details

MGRX has shown weak momentum, losing -22.09% over the past week and -74.41% over the past quarter, though year-to-date performance is down -17.35%. Short-term trend indicators are bullishly aligned (SMA20 25.4%, SMA50 -16.78%, SMA200 -66.21%). The stock’s 14-day RSI is 51.79 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -90.26% below its high and over 52.6% above its low. Average 10-day trading volume of 396.93 thousand shares is below the 3-month average of 12.67 million, indicating normal recent market interest.

Mangoceuticals, Inc. has 17.17 million shares outstanding. The public float is 13.43 million shares, elevated short interest at 1.35% of float. This equals 207.87 thousand shares. The short ratio is 0.09 days. Institutional investors hold 5.53% of the float. Insiders own 10.04%. Cohen Jacob D. holds 8.28 million shares, JOHNSTON EUGENE M has 120.00 thousand shares and Hamilton Alex P. has 3.33 thousand shares.

Mangoceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.31. This means the shares are trading below this model’s fair value.

Mangoceuticals, Inc. (NASDAQ:MGRX) closed at $0.45 USD, losing -$0.01 (-1.64%) from the previous close of $0.45. The stock is currently mid-range between its 52-week high and low $0.16 and $2.75. With a market capitalization of about $7.55 million, Mangoceuticals, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.05). Key stats such as the average daily volume over the past year has been around 13.81 million shares, volume is running light vs its 52-week average. Headquartered in Dallas, TX, Mangoceuticals, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Jacob D. Cohen, the company employs approximately 3 people and listed since March 21, 2023. Mangoceuticals, Inc. dedicates its operations to the creation, promotion, and distribution of a variety of health and wellness products and services specifically designed for men.

Mangoceuticals, Inc. trades at a P/E ratio of -0.39, slightly below the S&P 500 average, with a price-to-sales ratio of 24.32 and a price-to-book ratio of 0.62 suggesting the stock is closer to book value. The P/FCF stands at -1.97, also below market averages.

Our AI price prediction model suggests that Mangoceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -12.36%, with price expected at $0.39 by September 30, 2026, within a range of $0.32 to $0.46 3-Month Outlook: Projected fall of -79.78%, reaching $0.09 by December 15, 2026, with a range of $0.02 to $0.16. 1-Year Outlook: Projected loss of -93.26%, with price at $0.03 by September 17, 2027, within a range of $0.00 to $0.00.

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are down -17.35% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Mangoceuticals, Inc. trading at a premium to the broader market with a P/E of -0.39. Our AI forecast model points to short-term weakness (-12.36% over two weeks), a medium-term fall (-79.78% over three months), and a longer-term loss (-93.26% over one year), with expected trading ranges indicating moderate volatility.